InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,332.00
(
0.63%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.55
(
-0.18%
)
Bitcoin
61,180.00
(
0.00%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Biowatch

Send PM Follow Ignore
Followers 61
Posts 6668
Boards Moderated 1
Alias Born 10/18/2003

Biowatch

Member Level

Re: None

Thursday, 04/15/2010 5:18:52 AM

Thursday, April 15, 2010 5:18:52 AM

Post# of 252939
IDIX Positive Results With IDX184 From Interim Analysis of Phase IIa Hepatitis C Study

Idenix Pharmaceuticals Reports Positive Results With IDX184 From Interim Analysis of Phase IIa Hepatitis C Study
-- IDX184 50 and 100 mg cohorts in combination with pegylated interferon and ribavirin (PegIFN/RBV) demonstrated a favorable safety profile and potent antiviral activity at 14 days
-- Fifty percent of subjects receiving a total daily dose of 100 mg IDX184 achieved undetectable virus levels by Day 14
-- Study continuing with enrollment of 150 mg cohort


http://finance.yahoo.com/news/Idenix-Pharmaceuticals-prnews-3111503245.html?x=0&.v=1
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up